Chan Beals

Director Técnico/Científico/I+D en Abide Therapeutics, Inc. .

Health Technology

Finance

Cargos activos de Chan Beals

Empresas	Cargo	Inicio	Fin
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Director Técnico/Científico/I+D	06/01/2016	-

Massachusetts Institute of Technology

Undergraduate Degree

Internacional

Estados Unidos

Operativa

Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sectorial

Health Technology	2
Finance	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas privadas	1
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Health Technology

Empresas privadas

Health Technology